Unicycive Therapeutics Inc

Unicycive Therapeutics Inc has a market capitalization of $219.74 million and a price-to-book ratio of 7.28, indicating that the market is valuing the company at a premium to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. The current ratio of 2.59 indicates that the company has sufficient current assets to cover its current liabilities. The company's profitability metrics are negative, with a return on equity of -87.94% and a return on assets of -54.04%. These figures indicate that the company is not generating returns for its shareholders and is underperforming in terms of asset utilization. The operating income and net income are both negative, at -$29.52 million and -$26.56 million, respectively, highlighting the company's current financial challenges. Unicycive Therapeutics Inc's revenue concentration and geographic exposure are not explicitly detailed in the available data. However, the company's operations are primarily focused on the development and commercialization of therapies for neurological and psychiatric disorders, which may involve a diverse set of markets and customer segments. The lack of detailed segment data limits the ability to assess specific revenue concentrations. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow is negative at -$31.32 million, and the free cash flow is also negative at -$26.55 million, indicating that the company is not generating positive cash flows from its operations. The capital expenditure is relatively low at -$24,000, suggesting minimal investment in new assets. The risk assessment for Unicycive Therapeutics Inc indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and the custom valuations do not show any significant adjustments that would indicate a high risk of dilution. Recent events and filings for Unicycive Therapeutics Inc do not show any significant developments that would impact the company's financial position or strategic direction. The company's analyst estimates suggest a wide range of price targets, with a mean of $38.88 and a median of $31.00, indicating a high level of uncertainty among analysts regarding the company's future performance.